Clinical Trials

67 results for Prostate Cancer


A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Re

  • Condition: Metastatic Castrate Sensitive Prostate Cancer
  • Study ID: NCT04497844
View Trial

A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer

  • Condition: Metastatic Prostate Cancer, Prostate Adenocarcinoma
  • Study ID: NCT04446117
View Trial

A Phase Ib, Open-Label, Multicenter Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer.

  • Condition: Castration-Resistant Prostatic Cancer
  • Study ID: NCT04404140
View Trial

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients With DeNovo Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTE

  • Condition: Hormone-Sensitive Prostate Cancer
  • Study ID: NCT04493853
View Trial

Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study

  • Condition: Prostate Cancer
  • Intervention: Drug: AZD1775, Drug: Savolitinib, Drug: Darolutamide
  • Study ID: NCT03385655
View Trial

A Study to Evaluate the Safety and Efficacy of IMMU-132 (Sacituzumab Govitecan) in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed Therapy

  • Condition: Prostate Cancer
  • Intervention: Drug: IMMU-132
  • Study ID: NCT03725761
View Trial

Phase I/II Dose-escalation Study of Fractionated and Multiple Dose 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

  • Condition: Prostate Cancer
  • Study ID: NCT04506567
View Trial

ENZA-p: A Randomised Phase II Trial Using PSMA as a Therapeutic Agent and Prognostic Indicator in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide

  • Condition: Metastatic Castration-Resistant Prostate Cancer
  • Study ID: NCT04419402
View Trial

Changes in 18F-fluciclovine Positron Emission Tomography (PET) in Patients With Metastatic Castration Resistant Prostate Cancer Treated With Abiraterone Acetate: A Pilot Study

  • Condition: Metastatic Castration-resistant Prostate Cancer
  • Study ID: NCT04158245
View Trial

A Phase 3, Open-Label, Randomized Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)

  • Condition: Metastatic Castration-Resistant Prostate Cancer
  • Study ID: NCT04647526
View Trial

A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients With Advanced Prostate Cancer Refractory to Androgen Therapy

  • Condition: Advanced Prostate Cancer
  • Intervention: Biological: HPN424
  • Study ID: NCT03577028
View Trial

A Randomized Phase II Study of 177 LuPSMA-617 vs Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease

  • Condition: Prostate Cancer
  • Study ID: NCT04663997
View Trial

PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer

  • Condition: Prostatic Neoplasms
  • Study ID: NCT04689828
View Trial

Study of the Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Radionuclide Therapy Prior to Radical Prostatectomy in Men With High-risk Localised Prostate Cancer

  • Condition: Prostatic Neoplasms
  • Study ID: NCT04430192
View Trial

UpFrontPSMA : A Randomised Phase 2 Study of Sequential 177Lu-PSMA617 and Docetaxel Versus Docetaxel in Metastatic Hormone-Naive Prostate Cancer

  • Condition: Metastatic Hormone Naive Prostate Cancer
  • Study ID: NCT04343885
View Trial

A Validation Study on the Impact of Decipher® Testing on Treatment Recommendations in African-American and Non-African American Men With Prostate Cancer (VANDAAM Study)

  • Condition: Prostate Cancer
  • Intervention: Other: Decipher® Testing
  • Study ID: NCT02723734
View Trial

A Multicenter, Open-Label, Exploratory Platform Study to Evaluate Biomarkers and Immunotherapy Combinations for the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

  • Condition: Metastatic Castration-resistant Prostate Cancer
  • Intervention: Drug: NKTR-214 (Cohort A), Drug: Nivolumab (Cohort A and B), Radiation: Stereotactic body radiation therapy (SBRT) (Cohort B), Drug: CDX-301 (Cohort B), Drug: poly-ICLC (Cohort B)
  • Study ID: NCT03835533
View Trial
email news signup